Consolidation is still possible in the kidney-care sector, even though Fresenius Medical Care (NYSE: FMS) and DaVita HealthCare Partners (NYSE: DVA) appear to have about 90% of the U.S. market. Last week, DaVita announced its $415 million acquisition of Renal Ventures Management, LLC, a network of 36 dialysis clinics in six states, with headquarters in Lakewood, Colorado. RVM’s two physician divisions, Multispecialty Physician Partners and Physician Venture Partners were part of the deal. The second acquisition came from a much smaller player, privately held U.S. Renal Care, Inc. of Plano, Texas. The target was DSI Renal, owned by Frazier Healthcare and New Enterprise Associates, which currently operates 100 facilities in 22 states. Scaling up to meet the demands of CMS’s End-Stage Renal Disease (ESRD) Quality Incentive Program is one driver behind these deals, as CMS begins to pay for performance on quality measures, not quantity.